ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic he… Read more
ViroGates A/S (VIRO) - Total Assets
Latest total assets as of September 2025: Dkr14.21 Million DKK
Based on the latest financial reports, ViroGates A/S (VIRO) holds total assets worth Dkr14.21 Million DKK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ViroGates A/S - Total Assets Trend (2015–2024)
This chart illustrates how ViroGates A/S’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ViroGates A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
ViroGates A/S's total assets of Dkr14.21 Million consist of 99.0% current assets and 1.0% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 69.1% |
| Accounts Receivable | Dkr1.62 Million | 9.2% |
| Inventory | Dkr2.81 Million | 15.9% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr0.00 | 0.0% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how ViroGates A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ViroGates A/S's current assets represent 99.0% of total assets in 2024, an increase from 97.5% in 2015.
- Cash Position: Cash and equivalents constituted 69.1% of total assets in 2024, down from 83.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 15.9% of total assets.
ViroGates A/S Competitors by Total Assets
Key competitors of ViroGates A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
ViroGates A/S - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - ViroGates A/S generates 0.28x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ViroGates A/S is currently not profitable relative to its asset base.
ViroGates A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.81 | 8.30 | 5.43 |
| Quick Ratio | 1.58 | 6.13 | 5.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr6.29 Million | Dkr 12.21 Million | Dkr 30.71 Million |
ViroGates A/S - Advanced Valuation Insights
This section examines the relationship between ViroGates A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 39.12 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -28.1% |
| Total Assets | Dkr17.66 Million |
| Market Capitalization | $4.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values ViroGates A/S's assets below their book value (0.28 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ViroGates A/S's assets decreased by 28.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ViroGates A/S (2015–2024)
The table below shows the annual total assets of ViroGates A/S from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Dkr17.66 Million | -28.08% |
| 2023-12-31 | Dkr24.55 Million | +40.00% |
| 2022-12-31 | Dkr17.54 Million | -13.30% |
| 2021-12-31 | Dkr20.23 Million | -47.11% |
| 2020-12-31 | Dkr38.25 Million | -15.30% |
| 2019-12-31 | Dkr45.16 Million | -28.80% |
| 2018-12-31 | Dkr63.42 Million | +1174.07% |
| 2017-12-31 | Dkr4.98 Million | -58.51% |
| 2016-12-31 | Dkr12.00 Million | -31.11% |
| 2015-12-31 | Dkr17.41 Million | -- |